Calidi Biotherapeutics Presents CLD-101 Phase 1 Trial Update and Preclinical Data Highlighting RTNova and CLD-201 at 2024 ASCO Annual Meeting [Yahoo! Finance]
Calidi Biotherapeutics, Inc. (CLDI)
Company Research
Source: Yahoo! Finance
Showcased preclinical data on RTNova (CLD-400) platform's ability to survive bloodstream and reach all tumors systemically Non-clinical data supporting the upcoming SuperNova (CLD-201) clinical trial SAN DIEGO, June 03, 2024 BUSINESS WIRE )--Calidi Biotherapeutics Inc. (NYSE American: CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the presentation of three abstracts in a poster session during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. These posters, presented on June 1, 2024, include an update from the City of Hope-led Phase 1 study of Calidi's CLD-101 program, and preclinical data surrounding Calidi's RTNova (CLD-400) and CLD-201 platforms. "We are thrilled by the opportunity to present at ASCO and showcase the progress we have made across our various programs. Calidi's cutting edge approach to antitumor virotherapy is evident through the entirety of our pipeline, and
Show less
Read more
Impact Snapshot
Event Time:
CLDI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CLDI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CLDI alerts
High impacting Calidi Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CLDI
News
- Calidi Biotherapeutics Announces Appointment of Cancer Immunotherapy Pioneer Dr. George Peoples to Board of DirectorsBusiness Wire
- Calidi Biotherapeutics to Host Exclusive Live Investor Webinar and Q&A Session on June 13Business Wire
- Calidi Biotherapeutics Collaborates with SIGA Technologies to Advance Calidi's Revolutionary RTNova Virotherapy for Lung Cancer and Metastatic Solid Tumors [Yahoo! Finance]Yahoo! Finance
- Calidi Biotherapeutics Collaborates with SIGA Technologies to Advance Calidi’s Revolutionary RTNova Virotherapy for Lung Cancer and Metastatic Solid TumorsBusiness Wire
- Calidi Biotherapeutics Presents CLD-101 Phase 1 Trial Update and Preclinical Data Highlighting RTNova and CLD-201 at 2024 ASCO Annual MeetingBusiness Wire
CLDI
Sec Filings
- 6/26/24 - Form 8-K
- 6/20/24 - Form 4
- 6/20/24 - Form 4
- CLDI's page on the SEC website